The new facility replaces the company’s current Moscow depot and increases its size and capabilities--including local sourcing of comparator drugs and secondary packaging and labeling.
World Courier, a global provider of specialty logistics and a part of AmerisourceBergen, will open a new investigational drug depot in Moscow, Russia, in August. The new facility replaces the company’s current Moscow depot and increases its size and capabilities. New services, include local sourcing of comparator drugs and secondary packaging and labeling, which allows for late-stage customization of products.
Moscow remains an area of interest for clinical trials, and of the 123 new drug therapies approved by CDER in 2015, 50 were studied in Russia. Experts say the number of clinical trials in Russia could double by 2020.
Read the full release.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.